The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of UGT1A1 polymorphism on safety and dose management of sacituzumab govitecan in the treatment of advanced breast cancer patients.
 
Isabel Blancas
Honoraria - Adelphi Targis; AstraZeneca Spain; Bristol Myers Squibb; Cinfa; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Grunenthal; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; TACTICS; Transworld Editors; Veracyte; Veracyte
Consulting or Advisory Role - Adelphi Targis; AstraZeneca Spain; Cinfa; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Transworld Editors; Veracyte
Research Funding - Agendia (Inst); AstraZeneca Spain (Inst); Lilly; Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Other Relationship - Fundación San Juan de Dios; Medical Science Innovation Research (MEDSIR)
 
Lucia Gonzalez-Rivas
Speakers' Bureau - Pierre Fabre (I); Zambon (I)
Travel, Accommodations, Expenses - ROVI (I)
 
Marta Legerén
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Speakers' Bureau - AstraZeneca; Eisai; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Rocio Moron
No Relationships to Disclose
 
Fernando Rodríguez-Serrano
No Relationships to Disclose